The pharmaceutical industry has entered a period of transformation, focusing on the mainstream trend of the main industry of patent medicine enterprises

[pharmaceutical network industry trends] in recent years, with the introduction of policies, the state-owned hospitals and public hospitals are supported to reform, and social capital is encouraged to run hospitals In addition, under the influence of policies such as the key monitoring of auxiliary drugs, "two ticket system", the consistency evaluation of generic drugs, "4 + 7" centralized procurement with volume, medical insurance and fee control, many pharmaceutical enterprises have started to focus on the main business and control business risks better by stripping out the strategies that are not suitable for the development of enterprises and businesses that have no growth potential according to their own development needs Recently, Haier biology announced that it would transfer 75% of its equity in Haimei Kangji to Shanghai Huiqian enterprise management partnership for 27 million yuan After the completion of the transaction, Haier biology no longer has entities engaged in the research, development, production and sales of molecular diagnosis POCT related products According to the announcement, this is to reduce the company's operational risk, better promote the development of the main business and optimize the industrial layout In fact, Haier biology is not alone in launching the "slimming" program Since the beginning of 2020, domestic pharmaceutical enterprises such as Yuheng pharmaceutical and Haizheng pharmaceutical have issued asset sale announcements one after another On January 2, 2020, Yuheng pharmaceutical announced that the company has agreed to sell 100% of its shares in Aonuo (China) Pharmaceutical Co., Ltd to China Resources Sanjiu Pharmaceutical Co., Ltd Previously, the transfer price of the subject equity was RMB 1.42 billion after negotiation between the two parties It also mentioned in the announcement that the funds obtained from the sale of Aonuo pharmaceutical can give priority to the repayment of the company's debts, reduce the asset liability ratio and financial expenses, improve the debt structure, ensure the company's abundant cash flow and cope with the pressure of operating performance At the same time, Haizheng pharmaceutical also received sales news The auction of five apartments located in block a, Junyue building, Jiaojiang District, Taizhou city was successful, with a total transaction amount of 1.82 million yuan Up to now, the 27 apartments of the company located in block a, Junyue building, Jiaojiang District, Taizhou City have all been sold In fact, selling, selling and chopping are the key words of Haizheng pharmaceutical industry in 2019 It is understood that its purpose is also to sort out the fetters left by the original management, get rid of the burden and move forward lightly In fact, since 2019, at least many listed companies including Nanjing Pharmaceutical, Sihuan biology, Haizheng pharmaceutical, etc have divested or sold assets and businesses Nowadays, under the influence of the environment, the net profits of many listed pharmaceutical companies have begun to decline further, and they have to find new profit growth points, but this can not be achieved overnight Therefore, many pharmaceutical enterprises have started the mode of "selling, selling and selling" In fact, in addition to skinning ion companies, there are also enterprises to strengthen their competitiveness through acquisition For example, on December 21 last year, Zhejiang Jiuzhou Pharmaceutical Co., Ltd issued the announcement on the completion of 100% equity delivery of Suzhou Novartis Pharmaceutical Technology Co., Ltd., which formally incorporated Suzhou Novartis into its subsidiary On the whole, whether the pharmaceutical enterprises start the mode of "sell sell" or "buy buy buy", it proves that the external environment of the Chinese pharmaceutical industry is undergoing profound changes It can be predicted that in the future, for enterprises, combing their core capabilities and continuing investment, and at the same time, stripping or reducing non core businesses will become the mainstream of the industry for a period of time.